Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 1422 results for social care

  1. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Board

    Our board sets out our strategic priorities and policies.

  3. Executive team

    Biographies of the NICE executive team and minutes of their meetings

  4. Multiple long-term conditions: frailty register (IND206)

    This indicator covers the practice can produce a register of people with moderate to severe frailty. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM185

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  5. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  6. Blood transfusion (QS138)

    This quality standard covers the general principles of blood transfusion in adults, young people and children over 1 year old. It describes high-quality care in priority areas for improvement. It does not cover specific conditions that blood transfusion is used for.

    Quality standard
    Published
    15 December 2016
    View quality statements

    Sections for QS138

  7. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    In development [GID-TA11215] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  9. Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

    In development [GID-TA11316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  11. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 14 January 2025

    Technology appraisal guidance
    In development

  13. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    29 June 2023
    View quality statements

    Sections for QS8

  14. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Efgartigimod for treating generalised myasthenia gravis [ID4003]

    In development [GID-TA10986] Expected publication date: TBC

    Technology appraisal guidance
    In development